Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2007

01-04-2007 | Original Article

Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter

Authors: Rosalyn Juergens, Julie Brahmer, David Ettinger

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2007

Login to get access

Summary

Purpose

Gemcitabine and vinorelbine have demonstrated clinical efficacy both as single agents and in combination in patients with metastatic non-small cell lung cancer (NSCLC). This phase II trial evaluated biweekly gemcitabine and vinorelbine in NSCLC patients who have had one prior chemotherapeutic regimen and have had disease progression.

Methods

Gemcitabine (1,200 mg/m2 IV over 30 min) was followed by vinorelbine (30 mg/m2 IV over 6–10 min) on days 1 and 15 of each 28 day cycle. Chemotherapy was given for six cycles unless disease progression or unacceptable toxicity was seen.

Results

From 11/1998 to 10/2000, 15 of 20 patients enrolled (6 males, 9 females) were evaluable for response and survival. Two patients had grade 4 neutropenia, and one patient had grade 4 thrombocytopenia. The only non-hematologic grade 3 toxicities were fatigue, phlebitis, and arthralgias. No objective responses were observed, but 11 patients had stable disease for a mean of 6 months. The median survival time was 9.4 months (95% CI = 4.2, 14.8), with a median time to progression of 4.2 months (95% CI = 1.9, 5.6). The 1 year survival was 47%.

Conclusions

While this schedule of gemcitabine and vinorelbine was well tolerated, it was felt to be inactive. In vitro and pharmacokinetic studies published after the completion of our trial, suggest gemcitabine followed by vinorelbine may have antagonistic effects leading to lower dose delivery of both drugs. Our study was the only study of gemcitabine and vinorelbine in second-line NSCLC in the literature without an objective response. Our study was the only second-line study that administered gemcitabine prior to vinorelbine. First-line studies in the literature that administered vinorelbine prior to gemcitabine had, on average, a 1.7 month higher median survival (10.0 vs. 8.3 mos; P value <0.001). Because of the lack of response, further studies using this drug sequence, dose, and schedule for gemcitabine and vinorelbine are not recommended.
Literature
1.
Ettinger DS (2002) Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer? Oncologist 7:226–233PubMedCrossRef
2.
Grilli R, Oxman AD, Julian JA (1993) Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866–1872PubMed
3.
Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F (1994) Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 106:861–865PubMed
4.
Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E (1993) Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342:19–21PubMedCrossRef
5.
Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087–1100PubMed
6.
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3–10PubMed
7.
Johnson SA, Harper P, Hortobagyi GN, Pouillart P (1996) Vinorelbine: an overview. Cancer Treat Rev 22:127–142PubMedCrossRef
8.
Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, Mattson KV, Ramlau R, Szczesna A, Fidias P, Millward M, Belani CP (2003) Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 21:3016–3024PubMedCrossRef
9.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, the Eastern Cooperative Oncology Group (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98
10.
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10PubMedCrossRef
11.
Kaplan E, Meier P (1958) Nonparametric estimation grom incomplete observations. J Am Stat Assoc 53:457–481CrossRef
12.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef
13.
Castellano D, Hitt R, Ciruelos E, Cortes-Funes H, Colomer R (2003) Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors. Ann Oncol 14:783–787PubMedCrossRef
14.
Tempero M, Plunkett W, Ruiz van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRef
15.
Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R, Skarin AT (2001) Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48:151–159PubMedCrossRef
16.
Budman DR, Calabro A, Kreis W (1998) In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs 9:697–702PubMedCrossRef
17.
Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V (2003) Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95:362–372PubMedCrossRef
18.
Cattel L, Airoldi M, Passera R, Cagliero E, Stella B, Goffredo F (2004) Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences. Pharm World Sci 26:238–241PubMedCrossRef
19.
Camps C, Martinez EN, Jaime AB (2000) Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 27:47–53PubMedCrossRef
20.
Chen YM, Perng RP, Lee CS, Lin WC, Tsai CM, Whang-Peng J (2003) Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol 26:567–570PubMedCrossRef
21.
Hainsworth JD, Burris HA III, Litchy S, Erland JB, Hon JK, Brierre JE, Greco FA (2000) Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial. Cancer 88:1353–1358PubMedCrossRef
22.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS (2002) The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95:340–353PubMedCrossRef
23.
Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M, Kalofonos HP (2001) Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer 37:972–978PubMedCrossRef
24.
Park YH, Lee JC, Kim CH, Ryoo BY, Kim HT (2004) Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 34: 245–249PubMedCrossRef
25.
Bajetta E, Chiara SS, De CD, Bidoli P, Mariani L, Zilembo N, Pozzi P, Procopio G (2000) Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial. Cancer 89:763–768
26.
Baron F, Cueva J, Grana B, Curiel T, Leon L, Vazquez F, Candamio S, Lopez R (2001) Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. Eur J Cancer 37:1381–1384PubMedCrossRef
27.
Chen YM, Perng RP, Yang KY, Liu TW, Tsai CM, Ming-Liu J, Whang-Peng J (2000) A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer. Chest 117:1583–1589PubMedCrossRef
28.
Esteban E, Fra J, Corral N, Valle M, Carrasco J, Sala M, Puerta J, Estrada E, Palacio I, Vieitez JM, Buesa JM, Lacave AJ (2002) Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer. Invest New Drugs 20:73–82PubMedCrossRef
29.
Gridelli C, Frontini L, Perrone F, Gallo C, Gulisano M, Cigolari S, Castiglione F, Robbiati SF, Gasparini G, Ianniello GP, Farris A, Locatelli MC, Felletti R, Piazza E (2000) Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer 83:707–714PubMedCrossRef
30.
Hirsh V, Langleben A, Ayoub J, Cormier Y, Pintos J, Iglesias JL (2001) Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial. Cancer 92: 830–835PubMedCrossRef
31.
Isokangas OP, Knuuttila A, Halme M, Mantyla M, Lindstrom I, Nikkanen V, Viren M, Joensuu H, Mattson K (1999) Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer. Ann Oncol 10:1059–1063PubMedCrossRef
32.
Katakami N, Sugiura T, Nogami T, Yamamoto H, Negoro S, Nakano T, Okamoto N, Takada Y, Kodama K, Ariyoshi Y (2004) Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908. Lung Cancer 43:93–100PubMedCrossRef
33.
Krajnik G, Wein W, Greil R, Marhold F, Mohn-Staudner A, Kummer F, Malayeri R, Zochbauer-Muller S, Huber H, Pirker R (1998) Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial. Eur J Cancer 34:1977–1980PubMedCrossRef
34.
Krajnik G, Mohn-Staudner A, Thaler J, Greil R, Schmeikal S, Marhold F, Deutsch J, Preiss P, Malayeri R, Schafer-Prokop C, Wein W, Huber H, Pirker R (2000) Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer. Ann Oncol 11:993–998PubMedCrossRef
35.
Laack E, Mende T, Benk J, Chemaissani A, Scholtze J, Lorenz C, Niestroy A, Dalhoff K, Muller T, Walter T, Durk H, Edler L, Hossfeld DK (2001) Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 37:583–590PubMedCrossRef
36.
Lilenbaum R, Cano R, Schwartz M, Siegel L, Lutzky J, Lewis M, Krill E, Barreras L, Davila E (2000) Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study. Cancer 88:557–562PubMedCrossRef
37.
Lorusso V, Carpagnano F, Frasci G, Panza N, Di RG, Cisternino ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De LM (2000) Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18:405–411
38.
Palmeri S, Leonardi V, Gebbia V, De Bella MT, Ferrau F, Faillu G, Spatafora M, Valenza R, Di VG, Vitello S, Carroccio R, Sciortino G, Vaglica M, Accurso V, Agostara B, Licata G (2001) Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 34:115–123PubMedCrossRef
39.
Beretta GD, Michetti G, Belometti MO, Gritti G, Quadri A, Poletti P, Labianca R (2000) Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br J Cancer 83:573–576PubMedCrossRef
40.
Chen YM, Perng RP, Chen MC, Tsai CM, Ming-Liu J, Whang-Peng J (2003) A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older. Lung Cancer 40:221–226PubMedCrossRef
41.
Feliu J, Lopez GL, Madronal C, Espinosa E, Espinosa J, Giron CG, Martinez B, Castro J, De lG I, Baron MG (1999) Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group. Cancer 86:1463–1469PubMedCrossRef
42.
Frasci G, Lorusso V, Panza N, Comella P, Nicolella G, Bianco A, De CG, Iannelli A, Bilancia D, Belli M, Massidda B, Piantedosi F, Comella G, De LM (2000) Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 18:2529–2536
43.
Kimura H, Kasahara K, Shibata K, Shirasaki H, Iwasa K, Yoshimoto A, Kita T, Fuzimura M, Nakao S (2004) A phase II trial of biweekly administration of vinorelbine (V) and gemcitabine (G) in elderly patients (Pts) with advanced non-small cell lung cancer (NSCLC) (meeting abstracts). J Clin Oncol 22:7331
44.
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9:1692–1703PubMed
45.
Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J (2000) Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 18: 1748–1757PubMed
46.
Cattel L, Recalenda V, Airoldi M, Tagini V, Arpicco S, Brusa P, Bumma C (2001) A sequence-dependent combination of docetaxel and vinorelbine: pharmacokinetic interactions. Farmaco 56: 779–784PubMedCrossRef
47.
de Jonge MJA, Loos WJ, Gelderblom H, Planting ASTh van der Burg MEL, Sparreboom A, Brouwer E, van Beurden V, Mantel MA, Doyle E, Hearn S, Ross G, Verweij J (2000) Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effects. J Clin Oncol 18: 2104–2115PubMed
48.
Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de BG, de BE, Verweij J (2002) The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13:583–593
49.
Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692–1703PubMed
50.
Hanna N, Shepherd FA, Fossella FV, Pereira JR, De MF, von PJ, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597
51.
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103PubMed
52.
Shepherd FA, Rodrigues PJ, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van KM, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132
Metadata
Title
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Authors
Rosalyn Juergens
Julie Brahmer
David Ettinger
Publication date
01-04-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-006-0304-8

Other articles of this Issue 5/2007

Cancer Chemotherapy and Pharmacology 5/2007 Go to the issue

Clinical Trial Report

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

Short Communication

Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas

Original Article

Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer

Original Article

Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours

Original Article

Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

Original Article

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits